Cilta-Cel Yields High MRD-Negativity Rates in Multiple Myeloma After Prior Anti-BCMA Treatment
Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.
Cilta-Cel Shows Durability in Relapsed/Refractory Multiple Myeloma
Overall response rate was 95%, including 75% of patients who achieved a complete response (CR) or better, with a median follow-up of 5.8 months at data cutoff.
Updated KarMMA Data of Ide-Cel in Multiple Myeloma: Larry D. Anderson Jr, MD, PhD
The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.
